Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab, Trastuzumab, Palbociclib, and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
NCT07299890Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab, palbociclib, exemestane in breast cancer, sponsored by Anhui Provincial Tumor Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07299890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299890.